SpineThera Announces Allowance of Patent

SpineThera Inc., a privately held pharmaceutical company, announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/561,797.  Jeff Missling, CEO, commented, “This new patent builds on our previously issued patent and furthers our intellectual property protection of our sustained-release, injectable micro-suspension technology, including our lead drug product candidate.”  SpineThera expects the patent to be issued within the next few months.

 About SpineThera:

SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.